Adult: For symptomatic treatment: As 0.6% nasal spray (665 mcg/spray): 2 sprays (1,330 mcg) into each nostril bid. Child: 6-11 years For symptomatic treatment: As 0.6% nasal spray (665 mcg/spray): 1 spray (665 mcg) into each nostril bid; ≥12 years Same as adult dose.
Ophthalmic Allergic conjunctivitis
Adult: For symptomatic management: As 0.1% solution: Instil 1 drop into the affected eye(s) bid at an interval of 6-8 hours. Treatment may be maintained for up to 4 months, if needed. As 0.2% or 0.7% solution: Instil 1 drop into the affected eye(s) once daily. Dosing recommendations may vary among countries and between individual products (refer to specific product guidelines). Child: ≥3 years For symptomatic management: As 0.1% solution: Same as adult dose. As 0.2% or 0.7% solution: Instil 1 drop into the affected eye(s) once daily. Dosage and treatment recommendations may vary among countries and between individual products (refer to specific product guidelines).
What are the brands available for Olopatadine in Malaysia?
Not intended for the treatment of contact lens-related irritation (ophthalmic). Children. Pregnancy and lactation.
Adverse Reactions
Significant: Nasal septal perforation, nasal ulceration, epistaxis, somnolence (nasal); blurred vision (ophthalmic). Eye disorders: Ocular discomfort, burning, stinging, pain or pruritis, dry eye syndrome, foreign body or abnormal sensation in eyes, conjunctivitis, keratitis, superficial punctate keratitis, hyperaemia, eyelid oedema (ophthalmic). Gastrointestinal disorders: Bitter taste, xerostomia (nasal); dysgeusia, nausea (ophthalmic). General disorders and administration site conditions: Fatigue; asthenia, flu-like symptoms (ophthalmic). Immune system disorders: Hypersensitivity (ophthalmic). Infections and infestations: Influenza (nasal), infection (ophthalmic). Investigations: Weight gain, increased creatine phosphokinase (nasal). Musculoskeletal and connective tissue disorders: Back pain (ophthalmic). Nervous system disorders: Headache. Psychiatric disorders: Depression (nasal). Renal and urinary disorders: UTI (nasal). Respiratory, thoracic and mediastinal disorders: Cough; URTI (particularly in children), pharyngolaryngeal pain, throat irritation, postnasal drip (nasal); cold symptoms, rhinitis, sinusitis, pharyngitis (ophthalmic).
Patient Counseling Information
This drug may cause somnolence (nasal) and visual disturbances (ophthalmic), if affected, do not drive or operate machinery. Remove contact lenses before administration of ophthalmic solution and reinsert them after at least 15 minutes.
Monitoring Parameters
Nasal: Conduct a nasal examination prior to treatment initiation. Perform periodic nasal examinations to assess for nasal adverse effects (e.g. ulceration, perforation).
Overdosage
Nasal: Symptoms: Drowsiness (adults); initially, restlessness and agitation followed by drowsiness (children). Management: Symptomatic or supportive treatment.
Drug Interactions
Nasal: Potential additive CNS depression with CNS depressants.
Food Interaction
Nasal: May cause additive CNS depressant effects with alcohol.
Action
Description: Mechanism of Action: Olopatadine is a selective histamine H1-receptor antagonist that has mast-cell stabilising properties. It prevents the release of histamine from mast cells and inhibits histamine-induced inflammatory cytokine production by conjunctival epithelial cells. Onset: 30 minutes (nasal). Pharmacokinetics: Absorption: Bioavailability: 57% (nasal). Time to peak plasma concentration: 15 minutes to 2 hours (nasal). Distribution: Plasma protein binding: Approx 55% (mainly albumin). Excretion: Via urine (60-70% as unchanged drug); faeces (approx 17%). Elimination half-life: 8-12 hours (nasal); approx 3 hours (ophthalmic).
Chemical Structure
Olopatadine Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 5281071, Olopatadine. https://pubchem.ncbi.nlm.nih.gov/compound/Olopatadine. Accessed July 26, 2024.
Storage
Nasal spray: Store between 4-25°C. Ophthalmic solution: Store below 30°C. Storage recommendations may vary among countries and between individual products (refer to specific product guidelines).
S01GX09 - olopatadine ; Belongs to the class of other ophthalmologic antiallergics. R01AC08 - olopatadine ; Belongs to the class of topical antiallergic preparations, excluding corticosteroids. Used as antiallergic agents.
References
Anon. Olopatadine. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 04/07/2024.Brayfield A, Cadart C (eds). Olopatadine Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 04/07/2024.Joint Formulary Committee. Olopatadine. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 04/07/2024.Novartis New Zealand Limited. Patanol Eye Drops, Solution 0.1% w/v data sheet 30 May 2023. Medsafe. http://www.medsafe.govt.nz. Accessed 04/07/2024.Olopatadine (Nasal). UpToDate Lexidrug, Lexi-Drugs Multinational Online. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 04/07/2024.Olopatadine (Ophthalmic). UpToDate Lexidrug, Lexi-Drugs Multinational Online. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 04/07/2024.Olopatadine Nasal Spray, Metered (Akorn). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 04/07/2024.Opatanol 1 mg/mL Eye Drops, Solution (Novartis Pharmaceuticals UK Limited). https://products.mhra.gov.uk. MHRA. Accessed 04/07/2024.Pataday 0.2% Once Daily Relief Solution (Alcon Laboratories, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 04/07/2024.Pataday 0.7% Once Daily Relief Solution (Alcon Laboratories, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 04/07/2024.Pataday Ophthalmic Solution 0.2% w/v (Novartis Corporation [Malaysia] Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 04/07/2024.Pataday Twice a Day Relief Solution (Alcon Laboratories, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 04/07/2024.Patanase Nasal Spray (Novartis Pharmaceuticals Corporation). U.S. FDA. https://www.fda.gov. Accessed 04/07/2024.Patanol 0.1% Ophthalmic Solution (Novartis Corporation [Malaysia] Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 04/07/2024.
Sign Out
